Abstract

EGFR and the PI3K-Akt signaling pathway are common targets in cancer therapy and are often reported to develop associated drug resistance. This chapter describes the development of bispecific antibodies against the EGFR and Notch signaling pathways and appears to be able to overcome the problems caused by these resistances.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.